BBIO - Why did BridgeBio Pharma stock go down today? Insider sales

2023-04-10 16:03:39 ET

• BridgeBio Pharma ( NASDAQ: BBIO ), a drug developer targeting genetic diseases, lost ~4% on Monday after a few leading members of its management team, including its chief executive, sold more than $2M worth of company shares.
• According to two separate regulatory filings on Friday, BridgeBio ( BBIO ) founder and CEO Neil Kumar and CFO Brian Stephenson sold over 175K company shares last week under a previously adopted trading plan.
• Kumar has trimmed its BBIO stake by ~2% after selling 120.0K shares at $15.46 for a total value of ~$1.9M. Meanwhile, Stephenson has slashed his ownership by ~35%, selling 55.5K shares at $15.45 in a transaction worth ~$857.7K.
• The insider sales come days after the company shares surged in reaction to rumors of a decision to cancel a conference presentation amid reports of potential takeover interest from big pharma.

For further details see: